Hormone-refractory prostate cancer: a shifting paradigm in treatment.
Prostate cancer, the most common male cancer, affects one in eight American men. Risk factors for the disease include increased age, race, and family history of prostate cancer. To date, surgery, radiation, and hormonal therapy have been the mainstays of treatment. In the past, chemotherapy served only a palliative role for men with prostate cancer and failed to produce a survival advantage or any significant measurable disease response. However, for the first time, docetaxel-based regimens have demonstrated improved survival in men with hormone-refractory prostate cancer in two different, large, phase III studies. Additionally, a number of novel agents are being developed with the hope that treatment for men with hormone-refractory prostate cancer will be improved. Oncology nurses provide critical symptom management strategies as well as education to men with prostate cancer and their partners. Therefore, maintaining current state of the knowledge about best practices and treatment for prostate cancer is crucial. This, in turn, directs efforts to educate patients and family members about treatments and management of side effects.
Gallagher
Eva
E
Genentech BioOncology, Shorewood, MN, USA. gallagher.eva@gene.com
Gapstur
Roxanna
R
D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D015507:Drugs, Investigational; D006801:Humans; D008297:Male; D010353:Patient Education as Topic; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing / Q000473:pathology; D012307:Risk Factors; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D043823:Taxoids; D000077143:Docetaxel